Immucor Forms Joint Venture with Kainos

“I have relied on TM Capital for a range of strategic and financial advice for several years. Their impact as our advisor is best evidenced by the fact that our market capitalization has grown from $75 million to over $1 billion over this period.”

- Edward L. Gallup, Chairman & CEO, Immucor, Inc.

	Immucor, Inc. (NASDAQ: BLUD) is a leading supplier of diagnostic reagents and automated instrumentation to ensure the safety of blood transfusions
	Immucor has established direct distribution in many global markets, but its Japanese distribution rights were exclusively held by Kainos Laboratories, Inc., a publicly traded Japanese company
	Immucor retained TM Capital to structure and negotiate the acquisition of the blood bank distribution division of Kainos and achieve direct distribution in Japan
	TM Capital assisted Immucor in the formation of a joint venture with Kainos providing Immucor with immediate 51% ownership of its Japanese distribution company and eventual 100% ownership

Client Press Release